Aisling Capital, Others Inject $48M Into Roka Bioscience

Law360, New York (January 6, 2012, 5:19 PM EST) -- Life science private equity firm Aisling Capital joined OrbiMed Advisors LLC, New Enterprise Associates Inc. and Tarrant Capital IP LLC in issuing $47.5 million in Series D financing for molecular testing technology company Roka Bioscience, the company announced Friday.

Roka closed on $27.5 million of the financing in December and expects to complete the round later this year, bringing the company's total amount raised to $104.7 million since its founding in September 2009.

The terms of the financing were not disclosed.

“We are very pleased with...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.